



(ENGLISH VERSION)

COMUNICACION OF OTHER RELEVANT INFORMATION

December 28th 2022

In accordance with the provisions of article 226 of the consolidated text of the Securities Market Law, approved by Royal Legislative Decree 4/2015, of October 23, and other concordant provisions, ATRYS HEALTH, S.A. ("ATRYS" or the "Company") communicates:

Purchase of 100% of Initia Oncología S.L.U. and 70% of Initia Research S.L.

ATRYS communicates that it has acquired 100% of Initia Oncología S.L.U. and 70% of Initia Research S.L. (hereinafter "INITIA"). INITIA, is a company specialized in the provision of medical oncology services in the Autonomous Community of Valencia, of recognized prestige with accredited care and research activity. In 2022 it has made more than 1,500 oncology consultations

The aggregate amount paid by both companies amounts to 2,250,000 euros at a fixed price and a variable payment ("earn out") amounting to 185,000 euros linked to compliance in 2024 with a series of conditions, among them, that produce the renewal of certain contracts with clients, reach a minimum EBITDA and that the vendors continue providing medical services in the company.

At the financial level, Initia's income in the 2021 financial year has been 2,114,000 euros. The company has no financial debt.

With this acquisition, ATRYS consolidates its leadership in cancer care at a national level, reinforcing its acquisition strategy as it did with the incorporation of Bienzobas in June of this year. INITIA is a company specialized in comprehensive care for cancer patients located in Valencia. It is one of the main Autonomous Communities in private health insurance with more than 500,000 insured. This investment allows Atrys to expand its national presence by starting its oncology activity in Valencia, where INITIA has collaboration agreements with the main health insurers.

Likewise, it allows Atrys to expand its medical team, incorporating a multidisciplinary group of professionals led by doctors Andrés Poveda, Carlos Fernández Martos and Antonio Llombart. This team, made up of opinion leaders in different subspecialties, reinforces Atrys' position in precision oncology and personalized medicine.

The information communicated has been prepared under the sole responsibility of the issuer and its directors.

Madrid, December 28th, 2022.

Isabel Lozano Fernández

CEO